Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract CancerDo‐Youn Oh, Juan W. Valle, Aiwu Ruth He et al.|NEJM Evidence|2022Cited by 1.1k
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerYelena Y. Janjigian, Hyun Cheol Chung, Kohei Shitara et al.|Nature|2021Cited by 687
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialYelena Y. Janjigian, Sun Young Rha, Akihito Kawazoe et al.|The Lancet|2023Cited by 461
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyDo‐Youn Oh, Juan W. Valle, Aiwu Ruth He et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 245
Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cellsPei‐Hua Lu, Shukui Qin|Oncotarget|2017Cited by 51